Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07597239 · ClinicalTrials.gov registry record · NA
Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization
A NA study, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT07597239: Active NA study, sponsored by Massachusetts General Hospital.
NCT07597239 is a NA study that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 130 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07597239, a NA study, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults 18 years and older with peripheral artery disease (PAD) who have undergone leg artery open or endovascular surgery. The main questions it aims to answer are: * Can TEG-PM results improve blood-thinning medication levels in participants at high risk for blood clots after surgery? * Can adjusting blood-thinning medications based on TEG-PM results lower the rate of blood clots forming in their revascularized leg after surgery? Participants will: * Have blood samples taken before surgery and at 1 week, 1 month, 2 months, 3 months, 6 months, and up to 9 months after surgery * Have blood-thinning medications (aspirin, clopidogrel, and/or ticagrelor) adjusted based on TEG-PM results during the first 3 months after surgery * Have one additional blood test to check if clopidogrel is working properly * Have their medical records reviewed for 6 months after their last visit to check on their health outcomes
Primary Outcome
Determine if platelet inhibition and aggregation for participants with coagulation profiles that place them at high risk for thrombosis can be improved to levels not associated with thrombosis following alteration of antiplatelet therapy. High risk is defined as platelet inhibition not greater than 30%, platelet aggregation not less than 70%, or ADP maximum amplitude not less than 42mm on thromboelastography with platelet mapping.
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
- DRUG Ticagrelor
- DIAGNOSTIC_TEST Platelet Reactivity Testing
- DIAGNOSTIC_TEST Thromboelastography with Platelet Mapping
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT07597239 still lists
NCT07597239 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 5 interventions - of which Aspirin is the first listed.
NCT07597239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07597239 about?
NCT07597239 is a clinical study titled "Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization". The goal of this clinical trial is to learn if a blood clotting test called thromboelastography with platelet mapping (TEG-PM) can guide blood-thinning medication decisions in adults 18 years and older with peripheral artery disease (PAD) who have undergone leg artery open or endovascular surgery. T...
What is the current status of trial NCT07597239?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 130 participants. The study started on 2022-12-14. Estimated completion is 2026-06.
What interventions are being tested in trial NCT07597239?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG), Ticagrelor (DRUG), Platelet Reactivity Testing (DIAGNOSTIC_TEST), Thromboelastography with Platelet Mapping (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07597239?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07597239's enrollment target sits among peer trials
130 733rd of 2000 higher than 1,257 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI